HFA
GRCE

Hoover Financial Advisors’s Grace Therapeutics GRCE Stock Holding History

Hoover Financial Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$0 Hold
10
– – ﹤0.01% 695
2021
Q1 		$0 Buy
+10
New +$347 ﹤0.01% 652

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hoover Financial Advisors's GRCE Position: Q2 2021 in Review

Hoover Financial Advisors held its Grace Therapeutics (GRCE) position steady in Q2 2021 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Hoover Financial Advisors first reported a position in GRCE in Q1 2021 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold GRCE as of Q2 2021.

  • Hoover Financial Advisors held 10 shares of Grace Therapeutics worth $0 as of Q2 2021.
  • Hoover Financial Advisors left its Grace Therapeutics share count unchanged in Q2 2021.
  • Grace Therapeutics made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #695 holding.
  • Hoover Financial Advisors first reported a position in Grace Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.